top of page
The Professional Network for Healthcare Experts
FDA approves Sun Pharma Ilumya for adults with active psoriatic arthritis
The FDA has approved Sun Pharma's Ilumya for adults with active psoriatic arthritis, expanding the IL-23 inhibitor beyond its established plaque psoriasis indication.
nuaxia
5 days ago2 min read
European Commission approves Icotyde for moderate-to-severe plaque psoriasis
The European Commission has authorised Icotyde for adults and adolescents with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.
nuaxia
Sep 231 min read
EMA recommends Icotyde for EU authorisation in moderate-to-severe plaque psoriasis
If authorised, Icotyde would become the first oral treatment targeting the interleukin-23 receptor available to eligible adults and adolescents in the EU.
nuaxia
Jul 272 min read
bottom of page